Non-Invasive Cancer Diagnostics Market – Global Industry Insights, Trends, Opportunity Analysis, 2021-2027 the new research from Coherent Market Insights has announced report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The Non-Invasive Cancer Diagnostics Market offers a summary of product specification, production analysis, technology, product type, considering key features such as gross margin, revenue & cost. Non-Invasive Cancer Diagnostics Market report provides key statistics on the Market status of the Non-Invasive Cancer Diagnostics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1651
Non-invasive cancer diagnostics are the procedures used to identify cancer with no incision into the body. Treatment and detection of cancer in early stages is vital for extended survival. The method of non-invasive detection of cancer is observed to be a rising preferred choice, due to its minimal pain or painless diagnostic method coupled with results having more accuracy. Methods of molecular based diagnosis are expected to surge over the forecast period owing to introduction of new detection methods based on biomarker. Furthermore, factors such as rising prevalence of cancer, rising rate of cancer screening, government initiatives, along with emerging technologies including next-generation sequencing is expected to propel growth of the global non-invasive cancer diagnostics market over the forecast period.
As per the Cancer Research UK, no tests of diagnosis presently are 100% sensitive within general practice. It suggests the unfulfilled demand of innovative diagnostic assay with increased efficiency. Efficiency of the molecular diagnostics to screen tissue and blood samples for detection of cancer fuels the R&D of biomarker-based method of molecular diagnostic, which is able to find abnormalities in the early cycle of development. Furthermore, as per the Genome Biology published article in 2017, the present research in detection of non-invasive cancer is targeting two classes of studies – biomarker development for a particular type of cancer and circulating tumor DNA (ctDNA) characterization for general detection of cancer, without seeking to predict particular cancer types. These studies will support manufacturers in developing better kits of cancer detection for molecular-based diagnostics.
Global Non-Invasive Cancer Diagnostics Market Drivers
Rising prevalence of cancer is a key factor expected to drive growth of the global non-invasive cancer diagnostics market over the forecast period. Cancer is the major factor affecting the global economy. For instance, as per the 2018 Factsheet by the World Health Organization (WHO), Cancer is a second major cause of mortality globally, which accounts for over 9.6 Mn deaths in 2018. Worldwide, over 1 among six deaths is resulted due to cancer.
Rising cancer detection rates is expected to boost the global non-invasive cancer diagnostics market growth over the forecast period. As per the researchers from the U.S. Breast Cancer Surveillance Consortium (BCSC), the cancer detection rate raised to 34.7 / 1,000 people in 2013, in comparison with 25.3 / 1,000 people in 2005. Moreover, non-governmental and governmental organizations are focused on increasing awareness for cervical and breast cancer and conducting screening program. The National Institute for Health and Care Excellence (NICE) is engaged in enhancing the diagnosis rates through revising draft guidelines for early detection of cancer. Moreover, rising cancer studies in drug development of cancer is expected to the global non-invasive cancer diagnostics market growth over the forecast period. The NCI’s Center to Reduce Cancer Health Disparities, in 2016, introduced the National ‘Screen to Save’ Colorectal Cancer Outreach and Screening Initiative. This initiative was focused at increasing the screening rate of colorectal cancer.
Global Non-Invasive Cancer Diagnostics Market – Regional Analysis
Based on region, the global non-invasive cancer diagnostics market is segregated into North America, Europe, Latin America, Asia Pacific, Africa, and Middle East. North America accounts for the largest share in the global non-invasive diagnostics market, due to rising prevalence of cancer, rising advancements in technology, enhanced reimbursement scenario, along with governmental initiatives in cancer screening within early stages. For instance, the American Cancer Society Guidelines, for cancer’s early detection offers several screening plans in different ages. For example, as per the guidelines women aged from 40 to 44 years must annually screen for the breast cancer. Furthermore, market companies within the region APAC are focused on agreements and partnerships, which is expected to propel growth of the global non-invasive cancer diagnostics market. For instance, Halifax, in April 2019, signed an agreement of exclusive distribution with Genecast for making available the Immunoscore assay in China.
Rising product launches for organic strategies for maintaining the market position is the major factor fueling growth of the global non-invasive cancer diagnostics market. For instance, NeoGenomics Laboratories Inc., in March 2019, announced the Ventana PD-L1 (SP142) Assay launch for testing of tumor tissue within patients having the subtype triple negative of breast cancer. This test is the U.S. Food and Drug Administration (FDA) approved for people who might react to TECENTRIQ, the immune checkpoint inhibitor, combined with chemotherapy.
Furthermore, Exosome Diagnostics, Inc., in 2016, launched the test ExoDx Prostate (IntelliScore). The test utilizes genetic information through urine sample for evaluating patient risk in high grade prostate cancer. Laboratory Corporation of America Holdings, in 2016, launched Epi proColon, a first DNA-based blood test, approved by the U.S. FDA for the screening of colorectal cancer.
Market players are focused upon inorganic strategies through constantly boosting the global non-invasive cancer diagnostics market. For instance, Biocartis Group, a Belgian company of molecular diagnostics, in November 2018, signed an agreement with the AstraZeneca to develop molecular diagnostic biomarker for lung cancer.
In 2017, a biopharmaceutical manufacturing and development company, Lonza, acquired the company focused on R&D, distribution and manufacturing of products exosome genome – HanaBioMaed Life Sciences OU. With this acquisition, the company would invest for developing early-stage exosome-based cancer screening as well as molecular diagnostic tests. In 2017, CORE Diagnostics in partnership with CellMax Life, introduces ctDNA-based liquid biopsy and genetic cancer risk test by CellMax throughout India.
Global Non-Invasive Cancer Diagnostics Market Taxonomy
Based on technology,
- Clinical Chemistry
- Molecular Diagnostics
Based on cancer type,
- Lung Cancer
- Solid Tumors
- Blood Cancer
- Breast Cancer
- Other Cancer Type
Based on geography,
- North America
- Latin America
- Asia Pacific
- Middle East
Buy This Complete Business Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/1651
Major Players Are: Roche Diagnostics, Hologic Inc., Qiagen, Gen-Probe Inc., Digene Corporation, Abbott Molecular, IVDiagnostics, Laboratory Corporation of America Holdings, OncoCyte Corporation, Arquer Diagnostics Ltd. and Affymetrix Inc.
Main points in Non-Invasive Cancer Diagnostics Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Non-Invasive Cancer Diagnostics Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Non-Invasive Cancer Diagnostics Industry Impact
Chapter 2 Non-Invasive Cancer Diagnostics Competition by Types, Applications, and Top Regions and Countries
2.1 Non-Invasive Cancer Diagnostics (Volume and Value) by Type
2.3 Non-Invasive Cancer Diagnostics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Non-Invasive Cancer Diagnostics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Non-Invasive Cancer Diagnostics Market Analysis
Chapter 6 East Asia Non-Invasive Cancer Diagnostics Market Analysis
Chapter 7 Europe Non-Invasive Cancer Diagnostics Market Analysis
Chapter 8 South Asia Non-Invasive Cancer Diagnostics Market Analysis
Chapter 9 Southeast Asia Non-Invasive Cancer Diagnostics Market Analysis
Chapter 10 Middle East Non-Invasive Cancer Diagnostics Market Analysis
Chapter 11 Africa Non-Invasive Cancer Diagnostics Market Analysis
Chapter 12 Oceania Non-Invasive Cancer Diagnostics Market Analysis
Chapter 13 South America Non-Invasive Cancer Diagnostics Market Analysis
Chapter 14 Company Profiles and Key Figures in Non-Invasive Cancer Diagnostics Business
Chapter 15 Non-Invasive Cancer Diagnostics Market Forecast (2021-2027)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027